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INTRODUCTION
In recent years, liver resection and liver transplantation have
been widely adopted in clinical practice for treatment of liver dis-
eases. Hepatic ischemia-reperfusion injury (IRI) occurs substan-
tially during liverresection with resection of the portal vein and/or
the hepatic artery, or liver transplantation and remains a major
cause of liver non-function or functional failure following liver sur-
gery. This IRI has become an obstacle which has restricted the
development of extensive liver resection and liver transplantation
using marginal liver donors.
The mechanism of hepatic IRI have been widely investigated,
but nevertheless remains largely unclear. More importantly, an
effective prevention or treatment method is still lacking. Therefore
in Experiment 1, FK506 (tacrolimus), which is a powerful immune-
suppressive agent and also a hepato-trophic agent for hepatic IRI
(1), was used to perform the hepatic warm ischemic experiment on
pigs. This was in order to identify the impact on liver damage of
ischemic time and the effects of FK506 on IRI ; serum liver function
tests ; bile flow ; biliary excretion rate of bromsulfophtalein (BSP) ;
and animal survival rates. Furthermore, in Experiment 2 an immuno-
staining by the anti -CD18 antibody was performed and the adhe-
sive state of neutrophils in the liver after reperfusion was exam-
ined in order to explore the mechanism of the protective effects
of FK506. As well, the vascular endothelium was examined with
the scanning electron microscope after reperfusion. Finally, in
Experiment 3 we examined the effect of FK506 on stress gastric
mucosal damage where the participation of superoxides had been
shown (2-4).
MATERIALS AND METHODS
Experiment 1
Twenty-three (23) female pigs weighing 18 to 24 kg were fasted
for twenty- four (24) hours prior to their participation in the experi-
ment. After the making of a porto-caval shunt and cannulation with
a tube into the common bile duct, clamping of the hepatic artery and
the portal vein at the portal triad allowed hepatic warm ischemia
to be carried out for various lengths of time.
The twenty-two (22) pigs were divided into four (4) groups.
Group 1 : 120 minutes clamping (n=5) without FK506 treatment.
Group 2 : 150 minutes clamping (n=5) without FK506 treatment.
Group 3 : 180 minutes clamping (n=7) without FK506 treatment.
Group 4 : 180 minutes clamping (n=5) with FK506 treatment.
For Group 4, FK506 1 mg/kg was injected intra-muscularly for
four (4) days pre-operatively.
All the animals were examined for survival rate ; serum liver func-
tion test such as total bilirubin, aspartate aminotransferase (AST),
alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) ;
bile flow ; the biliary excretion rate of BSP ; chemiluminesence of
the neutrophils in the peripheral blood ; and the histology of the
liver.
Initially, as a normal control, one (1) pig was used to ascertain the
bile flow, and the biliary excretion rate of BSP after 5 μg/kg of BSP
was injected intravenously. And BSP in the bile was measured for
five (5) minutes at one (1) hour after reperfusion and the biliary
excretion rate was calculated.
A monitor tube for portal vein pressure was inserted from the
branch of the superior mesenteric vein to the portal trunk, and a
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monitor tube for arterial pressure was inserted in the femoral ar-
tery. Arterial pressure and portal pressure were measured in real
time before declamping of the hepatic artery (HA) and the portal
vein (PV) for about seven minutes. After having observed it about
ten minutes until arterial pressure was stable after declamping of
HA and PV, portal vein pressure was measured after clamping in
Porto-Caval shunt in each three pigs of Group 3 and Group 4.
The intensity of chemiluminescence of the peripheral neutro-
phils was measured during ischemia and reperfusion, and was
compared between Group 3 and Group 4.
Experiment 2
Experiment 2 was carried out in order to explore the mechanism
of the protective effects of FK506 on the anti -CD18 antibody ; the
adhesive state of neutrophils in the sinusoid and the vascular en-
dothelium after reperfusion.
Twenty-two (22) male Wister rats, weighing 200 to 250 g were
fasted for sixteen (16) hours prior to the experiment. The rats were
divided into two (2) groups, that is, the group receiving FK506 and
the placebo group. Under pentobarbital anesthesia (50 mg/kg),
laparotomy was carried out on each rat. Clamping of the inflow in
the hepatic hilus was done for fifteen (15) minutes as warm ische-
mia. At thirty (30) minutes, three (3) hours, and twenty- four (24)
hours after reperfusion, the liver was excised following the removal
of blood from the whole body via the left ventricle with 140 cm H2O
pressure. An immuno-staining was performed using ant-CD18
antibody on a fresh frozen specimen of the liver. The number of
white blood cells in the liver stained with ant-CD18 antibody that
was found in one field of view of 200 magnification, was then meas-
ured. As well, the hepatic sinusoid was observed with the scanning
electron microscope on 30 minutes after reperfusion.
Experiment 3
Because it has been suggested that superoxides cause the origin
of stress gastric mucosa damage (2-4), the effect of FK506 on the
development of stress ulcers was examined in Experiment 3.
Thirty -nine (39) male Wister rats, weighing between 200 and
250 g, were fasted for sixteen (16) hours prior to the experiment.
The rats were placed in restraint gauge, and were dipped into a bath
with a constant temperature of 22 up to the xiphoid process. The
stress load time was six (6) hours. After that, the stomach of each
rat was excised, and fixated with a 1% formalin solution overnight.
The lengths of the bleeding plaques were then measured, and their
lengths expressed as an ulcer index.
To ascertain the time dependent effect and dose dependent ef-
fect, the ulcer index was examined and comparison was made
between the placebo group and the FK506 group of rats. The ulcer
index was compared between three groups (Group A : one (1) time
of FK506 1 mg/kg on the day of the examination ; Group B : two
(2) times of FK506 1 mg/kg, one (1) on the day before the exami-
nation and one (1) on the day of the examination ; Group C : three
(3) times of FK506 1 mg/kg, one (1) on the two (2) days prior to
the examination and one (1) on the day of the examination).
Next the ulcer index was compared between three (3) groups
of the dosage of FK506 0.1 mg/kg, 0.5 mg/kg, 1.0 mg/kg by twice
administration on the day before and the day of the examination.
Myeloperoxidase activity in the gastric mucosa was examined
and comparison made between the placebo group and the FK506
group of rats.
All animal procedures complied with the animal care guidelines
of the Institute of Animal Experimentation in the Medical School
of Kumamoto University.
STATISTICS
Statistical analyses were performed using the Student’s t - test
with a p value of less than 0.05 considered to be significant. Data
were shown as meanSD. Differences in survival were deter-
mined using the Kaplan-Meier Survival analysis.
RESULTS
Experiment 1
One (1) week survival (rate) was 5/5 (100%) in Group1 (120 min-
utes ischemia without FK506), 5/5 (100%) in Group 2 (150 minutes
ischemia without FK506), 1/7 (14.3%) in Group 3 (180 minutes
ischemia without FK506), and 5/5 (100%) in Group 4 (180 minutes
ischemia with FK506).
The results showed that all the pigs included in the experiment
survived until 150 minutes ischemia in the groups without FK506
(Groups 1 and 2). However, although six (6) of seven (7) cases
without FK506 died under 180 minutes ischemia (Group 3), all
five (5) cases with FK506 survived under 180 minutes ischemia
(Group4) [Figure1]
The biochemical data such as total bilirubin, AST, ALT, and LDH
values at one (1) hour after reperfusion were not different between
the four (4) groups.
The bile flow was 1,200 μl/5 minutes in the normal pig used as
control. By contrast, the bile flow at one (1) hour after reperfusion
was 890 μl/5 minutes in Group 1 ; 400 μl/5 minutes in Group 2 ;
240 μl/5 minutes in Group 3 ; and 490 μl/5 minutes in Group 4
(180 minutes ischemia with FK506 treatment). It was noted that the
bile flow in Group 4 was almost equal to that in Group 2 [Figure 2].
The biliary excretion rate of BSP was 70% in the normal control
pig, but it was 25% in Group 1 ; 13% in Group 2 ; 5% in Group 3 ; and
15% in Group 4, respectively. The biliary excretion rate in Group 4
(180 minutes ischemia with FK506 treatment) was almost equal to
that in Group 2 (150 minutes ischemia without FK506) [Figure 3].
The color of the liver was dark red into a map form, and the
hardness was also increased at fifteen (15) minutes after reperfu-
sion in Group 3 (180 minutes ischemia without FK506), on the
other hand, the liver was a bright red color in the whole uniform,
enhancement of hardness was also mild in Group 4 (180 minutes
ischemia with FK506) [Figure 4].
Figure 1. The 7-day survival rate is shown. All pigs survived for 7 days
in Group 1, 2, 4. However, 6 of 7 pigs died within 3 days by circulatory
disturbance or liver failure. Survival rate was a significant difference be-
tween Group 1, 2, 4, and Group 3 (p0.02).
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Since the results of portal pressure in each three pigs in Group 3
and Group 4 on portal pressure were the same, each one example
of Group 3 (left) and Group 4 (right) was shown in Figure 5 as
representative example. The portal pressure was increased soon
in Group 3 after clamping of the porto-caval shunt. However, it
did not increased in Group 4, showing clearly from these results
that FK506 improved micro- circulation of the liver after reperfu-
sion [Figure 5].
The intensity of chemiluminescence of neutrophils began to rise
from two (2) hours after hepatic warm ischemia, and continued to
rise until two (2) hours after reperfusion in Group 3. In contrast,
the intensity of chemiluminescence of neutrophils remained slightly
increased after reperfusion in Group 4 [Figure 6]. It is suggested
from these results that FK506 inhibits the activity of superoxides
as well as immunological metabolism.
Figure 2. Bile flow was 1,200 μl/5 minutes in normal pig as control,
but, bile flow on one hour after reperfusion was 890 μl/5 minutes in
Group 1, 400 μl/5 minutes in Group 2, 240 μl/5 minutes in group 3 and
490 μl/5 minutes in Group 4 (180 minutes ischemia with FK506 treat-
ment), respectively. And bile flow in Group 4 was almost equal to it in
Group2.
Figure 3. Biliary excretion rate of BSP was 70% in normal pig, but it
was 25% in Group 1, 13% in Group 2, 5% in Group 3, and 15% in Group 4,
respectively. Biliary excretion rate in Group 4 (180 minutes ischemia
with FK506 treatment) was almost equal to in Group 2 (150 minutes
ischemia without FK506).
Figure 4. The color of the liver surface at fifteen (15) minutes after
reperfusion was dark red in Group 3 (180 minutes ischemia without
FK506), and clear red in Group 4 (180 minutes ischemia with FK506).
Figure 5. Portal pressure was increased in Group 3 after clamping of
portocaval shunt. But it did not increased in Group 4. It was clear that
FK506 improved microcirculation of the liver after reperfusion from
these results.
Figure 6. The intensity of chemiluminescence of neutrophils began
to rise from 2 hours after hepatic ischemia, and continued to rise until 2
hours after reperfusion. In contrast, the intensity of chemiluminescence
of neutrophils remained slightly increased after reperfusion in Group 4.
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Microscopic findings of the liver in Group 3 at one (1) hour after
reperfusion showed balloon degeneration, sinusoidal dilatation
and inflammatory cell infiltration. In contrast, these findings were
minor in Group 4.
Experiment 2
Adhered and infiltrated leukocytes that were stained with anti -
CD18 antibody, were observed approximately four (4) times be-
fore ischemia in the placebo group of rats and in the FK506 group
at thirty (30) minutes following reperfusion. As well, a large num-
ber of adhered and infiltrated leukocytes were observed in the
placebo group between three (3) hours and twenty- four (24) hours
following reperfusion, while in the FK506 group, adhered and infil-
trated leukocytes decreased between three (3) hours and twenty-
four (24) hours, significantly less in comparison with the placebo
group [Figure 7].
The hepatic sinusoid was observed with the scanning electron
microscope on 30 minutes after reperfusion. The dilatation of the
vascular endothelial pore, ruptures of the sieve plate, and adhered
leukocytes were observed much more in the placebo group (left
photo). In contrast, the dilatation of the vascular endothelial pore,
ruptures of the sieve plate, and adhered leukocytes were hardly
observed (right photo) [Figure 8].
Experiment 3
After six (6) hours restriction a clear hemorrhagic ulcer was
seen in the placebo group of rats but not in the FK506 group [Fig-
ure 9].
As the administrated times increased (Groups A to C), the ulcer
index decreased, and its effect was improved more by FK506 in
Time dependent [Figure 10].
The ulcer index decreased as the dose of FK506 increased to
0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, and its effect was improved more
in Dose dependent [Figure 11].
The Myeloperoxidase activity rose to four (4) times that of the
control in the placebo group, but it was hardly the same as the
control in the FK506 group where the activity did not rise [Figure
12]. Myeloperoxidase activity in a gastric mucosa was controlled
by FK506 pre-treatment [Figure 12].
Figure 7. In the placebo group, a large number of adhered and infil-
trated leukocytes were observed until 3 hours and 24 hours. But in the
FK506 group, adhered and infiltrated leukocytes decreased on 3 hours
and 24 hours, and it was significantly less in comparison with the placebo
group.
Figure 8. The hepatic sinusoid was observed with the scanning elec-
tron microscope on 30 minutes after reperfusion. The dilatation of the
vascular endothelial pore, ruptures of the sieve plate, and adhered leu-
kocytes were observed much more in the placebo group (left photo). In
contrast, the dilatation of the vascular endothelial pore, ruptures of the
sieve plate, and adhered leukocytes were hardly observed (right photo)
Figure 9. A clear hemorrhagic ulcer was seen by 6-hour restriction
in the placebo group (left photo), but the ulcer was not seen in the FK506
group (right photo).
Figure 10. As the administrated times of FK506 increased (Group A
to C), the ulcer index decreased, and its effect was improved more by
FK506 in Time dependent.
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DISCUSSION
Hepatic IRI includes both warm and cold IRI- two types that
share similar pathophysiological processes. The mechanism of
hepatic IRI have been widely investigated, but nevertheless re-
mains largely unclear. The factors/pathways that have been impli-
cated in the hepatic IRI process include anaerobic metabolism,
mitochondria, oxidative stress, intracellular calcium overlord, liver
Kupffer cells (KCs) and neutrophils, and cytokines and chemoki-
nes.
During the state of hepatic ischemia, the metabolic pattern is
shifted from aerobic to anaerobic, the redox process of the hepa-
tocytes is blocked, ATP-dependent cellular metabolic activities
are gradually stopped, and intracellular ATP is rapidly depleted.
Conversely, there is an accumulation of acidic metabolites, such
as lactic acid and ketone bodies, which is caused by enhanced
anaerobic glycolysis. This is accompanied by hypo function of mito-
chondrial oxidative phosphorylation, resulting in the decrease of
pH values between tissues and cells, known as metabolic acidosis.
When the blood flow is reopened to the ischemic organ, the pH
values restore to normal after reperfusion, and further enhance
pH-dependent enzyme activation, such as activation of proteases
and phospholipases, further worsening the damage of tissues and
organ. This is called the pH paradox (5).
IRI has biochemical ramification. The oxidative stress plays a
key role in reperfusion injury. Many highly reactive molecules,
such as Reactive Oxygen Species (ROS), are induced during the
period of hepatic IRI. ROS can also damage endothelial cells and
destroy the integrity of the microvasculature.
Among the biochemical factors affected by IRI, calcium has an
especially important role. When the calcium level is elevated by
ischemia or hypoxia, oxidative stress, toxic substance release or
other harmful event occur, this is call Ca2+ overload. Intracellular
Ca2+ overload can activate Ca2+ -dependent enzymes such as cal-
pains, protein kinase C, and phospholipase C, and ultimately leads
to cell death or apoptosis.
The liver KCs and neutrophils are involved in the hepatic IRI
process. The KCs mainly mediate liver ischemic injury in the ear-
lier stage of reperfusion (within two (2) hours) by synthesizing
and releasing ROS and the pro- inflammatory cytokines tumor
necrosis factor -alpha (TNF-α) and interleukin (IL)-1β to further
activate liver sinusoidal endothelial cells, enhance the expression
of the adhesion molecules inter cellular adhesion molecule 1
(ICAM-1)/vascular cell adhesion molecule 1 (VCAM-1), further
promote the adhesion, migration, and chemotaxis of neutrophils
and endothelial cells and accumulate and activate neutrophils, re-
sulting in subsequent liver cell damage (6). Activation of neutro-
phils can directly damage liver cells by the release of oxidants and
proteases after reperfusion. Ultimately, myeloperoxidase (halide
form, such as Cl-) released from neutrophils changes hydrogen
peroxide (H2O2) into hypochlorous acid (HOCl), which is a potent
oxidant. These oxidants can directly cause liver cell damage and/
or induce protease-mediated injury through inactivation of the en-
dogenous anti -protease system (7, 8), suggesting that anti -oxidant
or anti -protease therapy would be helpful for preventing IRI. In
our experiment of stress gastric ulcer in rats, it is very interesting
that FK506 controlled the activity of myeloperoxidase of the gastric
mucosa significantly. It is considered that there is enough possibil-
ity to suppress the activity of myeloperoxidase which is released
upon hepatic IRI.
Cytokines play a dual role of anti - inflammatory and pro- inflam-
matory responses in the process of liver IRI. TNF-α is a key member
of the group of endogenous pro- inflammatory and anti - inflammatory
molecules, and is a critical factor in triggering the inflammatory
cascade. It is secreted by activated KCs and impacts on liver tissue
and distant organs through paracrine signaling and the endocrine
system (9). TNF-α can bind to the receptors on the surface of liver
cells to induce overproduction of the chemokine epithelial neutro-
phil activating protein-78 (ENA-78) and ROS, activate nuclear
factor (NF)-κB, mitogen-activated protein kinase, and c-Jun N-
terminal kinase (JNK), and cause liver injury directly (10). In ad-
dition, TNF-α also can up regulate expression of the chemokines
ICAM-1, VCAM-1 and P-selectin (11). Moreover, JNK and ROS
can directly act on liver cells to cause liver damage.
FK506 was discovered in 1984, it was among the first macrolide
immuno-suppressants discovered. It is produced by a type of soil
bacterium, Streptomyces Tsukubaensis. FK506 was named from
Fujisawa (Pharmaceutical Co) Kaihatsu (Development) Num-
bers (506). Tacrolimus is named as general name after develop-
ment of FK506, and it is derived from Tsukuba macrolide immuno-
suppressant (12).
FK506 controls the immuno-reaction that a T cell participates
in strongly. The reaction includes a cytotoxic T cell, production
restraint of IL2, IL3, INF-γ, expression control of IL2 receptor (13).
It has been reported that FK506, in addition to being a powerful
Figure 11. The ulcer index decreased as the dose of FK506 increased
to 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, and its effect was improved more in
Dose dependent.
Figure 12. The Myeloperoxidase activity in the gastric mucosa rose
to 4 times of control in the placebo group, but it was the hardly same as
control in FK506 group, and the activity did notrise.
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immuno-suppressive agent, is also a hepatotrophic agent (1). As
well, in view of the mechanisms of IRI mentioned above, this study
was undertaken to verify whether FK506 was effective in prevent-
ing IRI.
The three experiments in this study were carried out using pigs
and rats to know whether FK506 is effective for hepatic IRI. Based
on the results of these three (3) experiments, it is suggested that
FK506 has a protective effect on IRI by suppressing : the impair-
ment of sinusoidal endothelial cells ; the activation of KCs ; the
disturbance of micro-circulation ; oxidative stress ; inflammation ;
and the accumulation of leukocytes.
The calcineurin inhibitor FK506 (tacrolimus) acts through a
blockade of the intracellular calcineurin-calmodulin complex. This
blockade inhibits the calcium-dependent phosphorylation of the
nuclear factor of activated T cells (NFAT). As a consequence, IL-2,
which is normally involved in the activation of CD4+ and CD8+ T
cells, and the IL-2 receptor are downregulated. Thus, the inactiva-
tion of T cells is regarded as the central mechanism in the immuno-
suppressant properties of FK506 (tacrolimus) (14, 15).
In addition, FK506 (tacrolimus) might attenuate allogen- inde-
pendent hepatic IRI, which is characterized by the release of a
complex cascade of cytokines including IL-6 and TNF-α, the gen-
eration of ROS, the accumulation and transmigration of different
cell types (that is, lymphocytes, neutrophils, platelets), as well as
alterations of the microcirculation potentially causing graft dys-
function or even non-function (16). In this respect, T cells have
been shown to be critically involved in the induction of IRI of the
liver (17-20). A rapid recruitment of CD4+ T cells in hepatic sinu-
soids as early as 30 minutes after reperfusion is followed by their
migration through the endothelial barrier to injured hepatic tissue
(18). Although CD4+ T cells themselves are not cytotoxic, they
release a panel of cytokines, chemokines and adhesion molecules
which are potentially harmful to the organ. Moreover, CD4+ T cells
interact with platelets and KCs which further aggravate IRI (21).
Neutrophils are also actively involved in hepatic IRI. The accu-
mulation of neutrophils congests hepatic sinusoids and leads to the
release of proinflammatory cytokines (that is, TNF-α and IL-6),
as well as ROS (22). Adhesion molecules such as P-selectin and
ICAM-1 are involved in the process of neutrophil recruitment (23).
The application of FK506 (tacrolimus) decreases the expression
of these adhesion molecules, thereby attenuating neutrophil re-
cruitment (24, 25). In addition, direct suppressive effects of FK506
(tacrolimus) on the activation of KCs, which also release proinflam-
matory cytokines have been demonstrated in vitro (26).
Several experimental studies have demonstrated prospective
effects of FK506 (tacrolimus) on IRI following liver transplantation
(27-29). Despite their promising results, these models were based
on systemic pre-conditioning in the same way of our experiments.
If we would like to put into clinical practice upon the procurement
of donor organs, It is necessary to verify experimentally whether
there is protective effects for IRI with pre-conditioning of FK506
during donor’s liver extraction for a short time (23 hours). And
also an ex vivo FK506 (tacrolimus) treatment clinically may rep-
resent a solution to this problem. Recently experimental data in-
dicated a protective effect of an ex vivo FK506 (tacrolimus) rinse
in a model of experimental liver transplantation in rats (30). In this
study preservation of intracellular glutathione levels was suggested
as a potential mechanism, and FK506 increases glutathione me-
tabolism, which in turn may protect organ function by reducing
ROS toxicity.
The anti - inflammatory effect of FK506 (tacrolimus) was also evi-
dent in human liver biopsies after the transplantation of organs
rinsed with FK506 (tacrolimus) (31).
With respect to the microcirculation, direct effects of FK506
(tacrolimus) on the expression of vasoconstrictive substances
(endothelin-1) in endothelial cells have been shown, which might
further improve hepatic microcirculation (32). Increased levels
of ROS are known to be involved in the pathogenesis of IRI. The
application of FK506 (tacrolimus) in vivo is associated with a red-
uction of ROS (29). FK506 (tacrolimus) has also been found to
exert anti -apoptotic effects by preventing Fas- induced apoptosis
in human hepatocytes in vitro (33), as well as in an in vivo model
of IRI in rats (34). A decrease in liver apoptosis may contribute to
persisting protection of cellular integrity.
Preliminary clinical data have shown beneficial results of FK506
(tacrolimus) preconditioning in human liver transplantation. In a
previous trial, Peter et al. demonstrated a significant reduction of
aminotransferase levels following the transplantation of normal
livers rinsed with 20 ng/ml FK506 (tacrolimus) (35). Although the
results of this trial were promising, the clinical impact was limited
by the small number of patients included (n=20). However, the
study population was relatively small, and, as most patients received
healthy organs, the results cannot be directly compared to a study
of marginal grafts. Now a prospective randomized multicenter trial
to reduce IRI in transplantation of marginal liver grafts with an ex
vivo FK506 (tacrolimus) perfusion has been performed in a Ger-
many group (36), but a finalized report of the study is not yet re-
ported. We look to accessing the results of this study.
However, because the mechanism of the IRI is very complex, it
is difficult to do prevention and treatment of IRI with only the one
agent. It is necessary to use various synthetic agents with different
action mechanism for prevention and treatment of IRI.
OKY046 is a specific thromboxane synthetase inhibitor which
suppresses the production of Thromboxane A2 (TXA), works as
a powerful platelet aggregating agent. The action mechanism of
FK506 and OKY046 are completely different. Sasaki K, et al. (our
colleague) reported that all six (6) rat recipients receiving liver
transplantation from non-heart beating donor with sixty (60) min-
utes warm ischemia survived for fourteen (14) days by pretreat-
ment of FK506 and OKY046 (37). It was clear that these two (2)
drugs ameliorated graft viability. And Takeichi T, et al. reported
that pretreatment with ONO-4057 (Leukotriene B4 receptor an-
tagonist) in combination with tacrolimus produced additive effects
in a rat model of liver IRI (38).
Nitric oxide (NO)-based therapy has been applied for many
years to patients with pulmonary hypertension cardiopulmonary
disorders. The therapeutic application of NO in protecting the liver
from IRI has been emerging. A prospective randomized trial with
liver transplantation patients has demonstrated that NO inhalation
in liver recipients during the perioperative period of liver transplan-
tation significantly protects hepatocytes from apoptotic death,
accelerates the restoration of liver graft function, and reduces
hospital length of stay (39). However, large amounts of NO may
in turn paradoxically damage liver tissue by forming nitrogen
peroxide (40). Husser N. reported that low-dose FK506 in combi-
nation with aminoguanidine, which leads to a reduction of NO
levels, reduced IRI of the graft after liver transplantation in a rat
model (41).
There have been various experiments performed regarding
whether the drugs are something to suppress hepatic IRI, and SM-
SOD (superoxide dismutase by linking styrene co-maleic acid
butyl ester) and HSP, that derived from geranylgeranylacetone
and there have been reports that these are the effects of suppress-
ing the IRI (42-45).
Because it has been found that various drugs can control IRI in
this way, it is important to find the integrated method that can easily
have clinical applications.
Recently, Sheu GE et al. reported that N2 treatment significantly
reduced intestinal injury severity scores after ischemia-reperfusion
(I/R) injury in humanized mice, generated by transplanting human
lymphocytes into immunodeficient mice. Protection from I/R in-
jury correlated with blockade of human antibody deposition on
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small intestine (46).
This is a study from the new phase taking to I/R injury of the
organ, by all means, also verify that there is an effect of N2 against
hepatic I/R injury. We want you to have led to the clinical appli-
cation as an effective treatment of hepatic I/R injury early.
SUPPORTED
This study was supported by a Grand- in-Aid for Scientific Re-
search (No.01480328) from the Japanese Ministry of Education,
Science and Culture (S.T.).
CONFLICT-OF-INTERESTSTATEMENT
The authors report no relevant conflicts of interest.
AUTHOR CONTRIBUTIONS
Toshihiko Sawada practiced these three experiments as sub-
stantial person, and brought up a paper the results of these three
experiments ; Katsuhiko Inoue and Dairo Tanabe participated these
three experiments, and contributed to data collections ; Shunji
Kawamoto participated and guided the experiment using rats ;
Tatsuya Tsuji participated the warm ischemic experiment using
pigs and rats, and guided the data analysis ; Seiki Tashiro partici-
pated in the experimental design, the method, the data analysis,
and writing the manuscript as general manager. All members agree
to accept equal responsibility for accuracy of the contents of this
paper.
ACKNOWLEDGEMENT
The authors thank Dr. Masayasu Inoue, Professor Emeritus of
Osaka City Medical University for having these experiments under
his guidance in Kumamoto University era.
REFERENCES
1. Francavilla A, Barone M, Todo S, Zang O, Porter KA, Starzl
TE : Augmentation of rat liver regeneration by FK506 com-
pared with cyclosporine. Lancet 2(8674) : 1248-1249, 1989
2. Parks DA, Bulkly GB, Granger DN : Role of oxygen-derived
free radicals in digestive tract diseases. Surgery 94(3) : 425-
432, 1983
3. Salim AS : Gastric mucosal cytoprotection in the rat by scav-
enging oxygen-derived free radicals. Am J Med Sci 302(5) :
287-291, 1991
4. Salm AS : The significance of removing oxygen-derived free
radicals in the treatment of acute and chronic duodenal ul-
ceration in the rat. J Pharm Phamacol 42(1) : 64-67, 1990
5. Datta G, Fuller BJ, Davidson BR : Molecular mechanisms of
liver ischemia reperfusion injury ; insights from transgenic
knockout models. World J Gastroenterol 9 : 1683-1698, 2013
6. Zhou W, Zhang Y, Hosch MS, Lang A, Zwacka RM, Engelhardt
JF : Subcellular site of superoxide dismutase expression dif-
ferentially controls AP-1 activity and injury in mouse liver fol-
lowing ischemia/reperfusion. Hepatology 33 : 902-914, 2001
7. Boury NM, Czuprynski CJ : Listeria monocytogenes infection
increases neutrophil adhesion and damage to a murine hepa-
tocyte cell line in vitro. Immunol Lett 46 : 111-116, 1995
8. Nagendra AR : Mickelson JK, Smith CW : CD18 integrin and
CD54-dependent neutrophil adhesion to cytokine-stimulated
human hepatocytes. Am J Physiol 272 : G408-416, 1997
9. Gujral JS, Bucci TJ, Fahood A, Jaeschke H : Mechanism of cell
death during warm hepatic ischemia-reperfusion in rats : apop-
tosis or necrosis? Hepatology 33 : 397-405, 2001
10. Redaelli CA, Tian YH, Schaffner T, Ledermann M, Baer HU,
Dufour JF : Extended preservation of rat liver graft by induc-
tion of heme oxygenase-1. Hepatology 35 : 1082-1092, 2002
11. Peralta C, Fernandez L, Panes J, Prats N. Sans M, Pique JM,
Gelpi E, Rosello-Catafau J : Preconditioning protects against
systemic disorders associated with hepatic ischemia-repre-
fusion through blockade of tumor necrosis factor - induced P-
selectin up-regulation in the rat. Hepatology 33 : 100-113,
2001
12. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T,
Okuhara M, Kohsaka M, Aoki H, Imanaka H : FK506, a novel
immune-suppressant isolated from a Streptomyces. 1. Fer-
mentation, isolation, and physic-chemical and biological char-
acteristics, J Antibiot 40 : 1249-1255, 1987
13. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M,
Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki N, Ochiai T :
FK-506, a novel immune-suppressant isolated from a Strep-
tomyces.. Immuno-suppressive effect of FK-506 in vitro. J
Antibiolot 40(9) : 1256-1265, 1987
14. Banerji SS, Parsons JN, Tocci MJ : The immunosuppressant
FK506 specifically inhibits mitogen- induced activation of the
interleukin-2 promoter and the isolated enhancer elements
NFIL-2A and NF-ATI. Mol cell Biol 11(8) : 4074-4087, 1991
15. Ypshimura N, Matsui S, Hamashima T, Oka T : Effect of a new
immunosuppressive agent, FK506, on human lymphocyte
responses in vitro. 1. Inhibition of rxpression of alloantigen-
activated suppressor cells, as well as induction of alloreactiv-
ity. Transplantation 47(2) : 351-356, 1989
16. Jaeschke H : Molecular mechanisms of haptic ischemia-reper-
fusion injury and preconditioning. Am J Phisiol Gastrointest
Liver Physiol 283(1) : G15-G25, 2003
17. Zwacka RM, Zhang Y, Halldorson J, Schlossberg H, Dudus L,
Engelhardt JF : CD4(+) T- lymphocytes mediate ischemia/
repwefusion- induced inflamematory responses in mouse
liver. J Clin Invest 100(2) : 279-289, 1997
18. Khandoga A, Hanschen M, Kessler JS, Krombach F : CD4+T
cells contribute to postischmic liver injury in mice by inter-
acting with sinusoidal endothelium and platelets. Hepatology
43(2) : 306-315, 2006
19. Shen X, Wang Y, Gao F, Ren F, Busuttil RW, Kupiec-Weglinski
JW, Zhai Y : CD4 T cells prpmote tissue inflammation via
CD40 signaling without de novo activation in a murine model
of liver ischemic/reperfusion injury. Hepatology 50(59) : 1537-
1546, 2009
20. Zang Y, Ji H, Shen X, Cai J, Gao F, Koenig KM, Batikian CM,
Busuttil RW, Kupiee-Weglinski JW : Targeting TIM-1 on
CD4 T cells depresses macrophage activation and overcomes
ischemia-reperfusion injury in mouse orthotopic liver trans-
plantation. Am J Transplant 13(1) : 56-66, 2013
21. Hanschen M, Zahler S, Krombach F, Khandoga A : Reciprocal
activation between CD4+T cells and Kupffer cells during heap-
tic ischemia-reperfusion. Transplantation 86(5) : 710-718, 2008
22. Jaeschke H, Farhood A : Neutrophil and Kupffer cell - induced
oxidant stress and ischemia-reperfusion injury in rat liver.
Am J Physiol 260(3) : G355-G362, 1991
23. Yadav SS, Howell DN, Gao W, Steeber DA, Harland RC,
Clavien PA : L-slectin and ICAM-1 mediate reperfusioninjury
and neutron adhesion in the warm ischemic mouse liver. Am
J Physio 275(6 Pt 1) : G1341-G1352, 1998
24. Squadrito F, Altavilla D, Squadrinto G, Saitta A, Deodato B,
Arlotta M, Minutoli L, Quartarone C, Ferlito M, Caputi AP :
268 S. Tashiro, et al. Protective effects of FK506 for hepatic-IRI
Tacrolimus limits polymorphonuclear leucocyte accumulation
and protects against myocardial ischemia-reperfusion injury.
J Mol cell Cardiol 32(3) : 429-440, 2000
25. Garcia-Criado FJ, Lozano-Sanchez F, Fernandez-Regalado
J, Valdunciel -Garcia JJ, Parreno-Manchado F, Silva-Benito I,
Zambrano-Cuadrado Y, Gomez-Alonso A : Possible tacrolimus
action mechanisms in its protector effects on ischemia-reper-
fusion injury. Transplantation 66(7) : 942-943, 1998
26. Tojimbara T, Bermudez LE, Egawa H, Hayashi M, So SK,
Esquivel CO : Cyclosporine and tacrolimus both suppress ac-
tivation of Kupffer cells in vitro. Transplant Proc 28(3) : 1381-
1382, 1996
27. Sakr MF, Zetti GM, Hassanein TH, Gavaler JS, Starzl TE :
Protective effect of FK506 against hepatic ischemia in rats.
Yransplant Proc 23(1 Pt 1) : 340-341, 1991
28. Kawano K, Bowers JL, Kim, YI, Tatsuma T, Kitabo S,
Kobayashi M, Clouse ME : FK506 reduces oxidative hepatic
injury following cold ischemic preservation and transplanta-
tion. Transplant Proc. 28 : 1902-1903, 1998
29. Garcia-Criado FJ, Palma-Vargas JM, Valdunciel -Garcia JJ,
Toledo AH, Misawa K, Gomez-AAlonso A, Toledo-Pereyra
LH : Tacrolimus(FK506) down-regulates free radical tissue
levels, serum cytokines, and neutrophil infiltration after se-
vere liver ischemia. Transplantation 64(4) : 594-598, 1997
30. Pratschke S, Bilzer M, Grutzner U, Angele M, Tufman A, Jauch
KW, Schauer RJ : Tacrolimus preconditioning of rat liver al-
lografts impacts glutathione homeostasis and early reperfu-
sion injury. J Surg Res 176 : 309-316, 2012
31. Kristo I, Wilflingseder J, Kainz A, Marschalek J, Wekerle T,
Muthlbacher F, Oberbauer R, Bodingbauer M : Effect of in-
traportal infusion of tacrolimus on ischaemic reperfusion
injury in orthotopic liver transplantation : a randomized con-
trolled trial. Transpl Int 24(9) : 912-919, 2011
32. Soda Y, el -Assal ON, Yu L, Nagasue N : Suppressed endo-
thelin-1 production by FK506 and cyclosporin A in ischemia/
reperfusion of rat small intestine. Surgery 125(1) : 23-32,1999
33. Gomez-Lechon MJ, Serralta A, Donato MT, Jimenez N,
O’connor E, Castell JV, Mir J : The immunosuppressant drug
FK506 prevents Fas- induced apoptosis in human hepatocytes.
Biochem Pharmacol 68(12) : 2427-2433, 2004
34. Crenesse D, Laurens M, Heurteaux C, Cursio R, Saint -Paul
MC, Schmid-Alliana A, Gugenheim J : Rat liver ischemia-
reperfusion- induced apoptosis and necrosis are decreased by
FK506 pretreatment. Eur J Pharmacol 473(2-3) : 177-184,
2003
35. Peter S, Post DJ, Rodriguez-Davalos ML, Douglas DD, Moss
AA, Mulligan DC : Tacrolimus as a liver flush soluteon to ame-
liorate the effects of ischemia/reperfusion injury following
liver transplantation. Liver Transpl 9(2) : 144-149, 2003
36. Pratschke S, Eder M, Helse M, Nadalin S, Pascher A,
Schemmer P, Scherer MN, Ulrich F, Wolters H, Jauch KW,
Wöhling D, Angete MK : Protocol TOP-study (tacrolimus
organ perfusion) : a prospective randomized multicenter trial
to reduce ischemia reperfusion injury in transplantation of
marginal liver grafts with an ex vivo tacrolimus perfusion.
Transplant Res. 2 : 3 -13, 2013
37. Sasaki K, Miyake H, Kinoshita T, Ikeyama S, Tashiro S : Pro-
tective effect of FK506 and thromboxane synthase inhibitor
on ischemia-reperfusion injury in non-heart -beating donor
in rat orthotopic liver transplantation. J Med Invest 5 : 76-82,
2004
38. Takeichi T, Uemoto S, Minamiguchi S, Takeyoshi I, Inomata
Y, Tanaka K, Kobayashi E : Effect of ONO-4057 and tacrolimus
on ischemia-reperfusion injury of the liver. World J Gastro-
enterol 15 : 5712-5, 2009
39. Lang JD, Teng X, Chumley P, Crawford JH, Isbell S, Chacko
BK, Liu Y, Jhala N, Crowe DR, Smith AS, Cross RC, Frenette
L, Kelly EE, Wilhite DW, Hall CR, Page GP, Fallon MB, Bynon
JS, Eckhoff DE, Patel RP : Inhaled NO accelerates restoration
of liver function in adults following orthotopic liver transplan-
tation. J Clin Invest 117(9) : 2583-2591, 2007
40. Miyake T, Yokoyama Y, Kokuryo T, Mizutani T, Imamura A,
Nagino M : Endothelial nitric oxide synthase plays a main role
in producing nitric oxide in the superacute phase of hepatic
ischemia prior to the upregulation of inducible nitric oxide
synthase. J Surg Res 183 : 742-751, 2013
41. Husser N, Doll D, Altomonte J, Werner M, Kriner M, Preissel
A, Thorban S, Matevossian E : Graft preconditioning with
low-dose tacrolimus (FK506) and nitric oxide inhibitor ami-
noguanidine (AGH) reduces ischemia/reperfusion injury
after liver transplantation in the rat. Arch Pharm Res 32 : 215-
220, 2009
42. Kawamoto S, Inoue M, Tashiro S, Morino Y, Miyauchi Y : Role
of free radicals in entero-hepatic dysfunction caused by portal
circulatory disturbance : Effect of SOD derivative. Transplant
Proc 21 : 1287-1289, 1989
43. Kawamoto S, Inoue M, Tashiro S, Morino Y, Miyauchi Y :
Inhibition of ischemia and reflow-induced liver injury by an
SOD derivative that circulates bound to albumin. Arch Bio-
chem Biophys 277 : 160-165, 1990
44. Oda H, Miyake H, Iwata T, Kusumoto K, Rokutan K, Tashiro
S : Geranylgeranylacetone suppresses inflammatory responses
and improves survival after massive hepatectomy in rats. J
Gastrointest Surg 6 : 464-473, 2002
45. Kanemura H, Kusumoto K, Miyake H,Tashiro S, Rokutan, K,
Shimada M : Geranylgeranylacetone prevents acute liver dam-
age after massive hepatectomy in rats through suppression of
a CXC chemokaine GRO1 and induction of heat shock pro-
teins. J Gastrointest Surg 13 : 66-73, 2009
46. Sheu EG, Wakatsuki K, Oakes S, Carroll MC, Moore FD jr :
Prevention of intestinal ischemia-reperfusion injury in hu-
manized mice. Surgery 2018 Apr 16
The Journal of Medical Investigation Vol. 63 August 2016 269
